GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » Cash Flow from Investing

Caribou Biosciences (Caribou Biosciences) Cash Flow from Investing : $-68.18 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Caribou Biosciences spent $2.28 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $84.19 Mil on purchasing investments. It gained $55.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Caribou Biosciences spent $31.47 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Caribou Biosciences Cash Flow from Investing Historical Data

The historical data trend for Caribou Biosciences's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caribou Biosciences Cash Flow from Investing Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
27.23 6.36 -176.40 -93.25 -68.18

Caribou Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 20.70 11.06 -68.48 -31.47

Caribou Biosciences Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Caribou Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Caribou Biosciences's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Caribou Biosciences  (NAS:CRBU) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Caribou Biosciences's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-2.28 Mil. It means Caribou Biosciences spent $2.28 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Caribou Biosciences's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Caribou Biosciences gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Caribou Biosciences's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Caribou Biosciences spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Caribou Biosciences's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Caribou Biosciences gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Caribou Biosciences's purchase of investment for the three months ended in Dec. 2023 was $-84.19 Mil. It means Caribou Biosciences spent {stock_data.stock.currency_symbol}}84.19 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Caribou Biosciences's sale of investment for the three months ended in Dec. 2023 was $55.00 Mil. It means Caribou Biosciences gained $55.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Caribou Biosciences's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Caribou Biosciences paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Caribou Biosciences's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Caribou Biosciences paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Caribou Biosciences's cash from other investing activities for the three months ended in Dec. 2023 was $-0.00 Mil. It means Caribou Biosciences paid $0.00 Mil for other investing activities.


Caribou Biosciences Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Caribou Biosciences (Caribou Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Executives
Syed Ali-aamir Rizvi officer: Chief Medical Officer C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner officer: See Remarks CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson director C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Barbara G Mcclung officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan officer: Chief Business Officer C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Dara Richardson-heron director C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng director 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting director 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Rachel E. Haurwitz director, officer: See Remarks C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Andrew Guggenhime director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710